Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46

Trial Profile

Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Tigilanol tiglate (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors QBiotics
  • Most Recent Events

    • 08 Jul 2017 Status changed from recruiting to completed.
    • 06 Sep 2016 Planned number of patients changed from 30 to 15.
    • 26 Nov 2014 Status changed from not yet recruiting to recruiting, as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top